Filters
Publications
Displayed are Syndax Sponsored Studies. Search results may include information that is not consistent with the product's Full Prescribing Information. Syndax does not recommend uses that are inconsistent with the Full Prescribing Information.
American Thoracic Society
(Axatilimab) Safety, Tolerability, and Efficacy of Axatilimab, a Colony-Stimulating Factor 1 Receptor (CSF-1R) Humanized Antibody, in Advanced Chronic Graft-versus-host Disease-Related Bronchiolitis Obliterans Syndrome
2023
American Society of Hematology
(Axatilimab) Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)
2023
American Society of Hematolog
(Revumenib) Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal AUGMENT-101 Phase 2 Study
2023
Journal of Clinical Oncology
(Axatilimab) Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study
2022
American Association for Cancer Research
(Axatilimab) SNDX-6352-0502 – A Phase 1, Open-Label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Axatilimab (SNDX-6352) Monotherapy in Patients With Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors
2020
American Society of Hematology
(Axatilimab) Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, For Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment
2020
Science
(Revumenib) Therapeutic Targeting of Preleukemia Cells in a Mouse Model of NPM1 Mutant Acute Myeloid Leukemia
2020
Clinical Translation of Epigenetics in Cancer Therapy Conference
(Revumenib) Targeting the Menin MLL1 Interaction Site as a Treatment for Mixed Lineage Leukemia rearranged (MLL r) and NPM1c+ AML
2019
Cancer Cell
(Revumenib) A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of of MLL-Rearranged Leukemia
2019
American Association for Cancer Research
(Revumenib) Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia
2018